Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring

Status Recruiting

Clinical Trial Summary

It is not known if the use of NuvaRing® alters these innate and inflammatory biomarkers of inflammation.

Hypothesis:

The hypothesis is that NuvaRing® will alter inflammatory biomarkers of inflammation, such as vaginal defensin and cytokine levels, resulting in an overall anti-inflammatory milieu in the vagina.

Specific aims of this study are to:

1. Determine biomarkers of inflammation, including defensins and cytokines, concentrations in women with normal vaginal flora (Nugent Score 0 - 3) before and after NuvaRing® use

2. Determine changes in the integrity of cervicovaginal epithelium and leukocytic concentration before and after treatment with NuvaRing®

3. Monitor for changes in the Nugent score before and after NuvaRing® use

4. Assess the antimicrobial activity of vaginal fluid before and after NuvaRing® use

5. Assess HIV infectivity ex vivo on biopsy specimens before and after NuvaRing® use

Methods This is a prospective, open-label, nonrandomized study. Participants will serve as their own controls. The Clinical Research Center of Eastern Virginia Medical School, Norfolk, Virginia, U.S.A. will be the only study site.

Clinical Trial Description

1. To complete specific aim #1, the investigators will use commercially available elisa kits to measure human defensins, inflammatory cytokines, and anti-inflammatory cytokines in vaginal fluid washings collected before and after use of NuvaRing.

2. To complete specific aim #2, the investigators will collect biopsies of the uterine cervix before and after NuvaRing use. Specimens will undergo histopathological measures for overall appearance, epithelial integrity, epithelial thickness, leukocyte infiltration, congestion, and edema. The investigators will quantitate the number of CD45+ and NFkB+ cells using immunohistology in the cervical epithelium. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Vaginosis, Bacterial

Clinical Trial Details

NCT number	NCT01448291
Study type	Interventional
Source	Eastern Virginia Medical School
Contact	Julia Caul
Phone	7574465808
Status	Recruiting
Phase	Phase 4
Start date	October 2011
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT02558179` - Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method	N/A
Completed	`NCT02272231` - Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women
Completed	`NCT02314429` - Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis	Phase 1
Completed	`NCT02139839` - Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14	Phase 0
Recruiting	`NCT03500107` - Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial	N/A
Completed	`NCT00153517` - Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy	Phase 2
Completed	`NCT04989543` - Study of the Composition and Bacterial Diversity of the Vaginal Microbiota in Healthy Versus Pathological Conditions (Bacterial Vaginosis) Using a Targeted Metagenomic Approach (RNA 16s)	N/A
Completed	`NCT02641717` - Validity of Patient-Collected Wet Mounts	N/A
Terminated	`NCT03943823` - Postmenopausal Pessary Users: Estrogen Versus Trimosan	Phase 4
Completed	`NCT03134924` - Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention "WASH-2"	N/A
Completed	`NCT01293643` - A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)	Phase 3
Terminated	`NCT01153958` - Colposeptine for the Treatment of Bacterial Vaginosis	Phase 4
Completed	`NCT00484653` - Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman	N/A
Completed	`NCT05649735` - EFFICACY AND SAFETY OF OVA AND LAVAGE MEDICAL DEVICES IN THE TREATMENT OF NON-SPECIFIC VULVOVAGINITIS	N/A
Completed	`NCT02860845` - Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections	Phase 4
Not yet recruiting	`NCT00491270` - Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery	Phase 3
Completed	`NCT01055106` - Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis	Phase 2
Terminated	`NCT01322971` - Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population	N/A
Completed	`NCT04171947` - Vaginal Ovule With Flavonoid Tea Extract for the Correction of Imbalance in the Vaginal Environment	N/A
Completed	`NCT02392026` - Safety and Tolerability of Metronidazole Gel 1.3%	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms